Healthscope Ltd slumps on sale of its Asian Pathology operations


Sale of Asian Pathology operations to TPG Capital Asia as per strategic review: Healthscope Ltd.’s (ASX: HSO) stock fell 1.12% on July 30, 2018 after the company signed an agreement to sell its Asian Pathology operations in Singapore, Malaysia and Vietnam for the consideration of A$279 million, to entities controlled by funds that are managed by TPG Capital Asia. TPG Capital Asia is the Asia’s investment platform within the global alternative asset firm, TPG. The consideration is on a cash-free and debt-free basis and is subject to customary completion adjustments. Overall, the transaction is expected to be completed by the end of August 2018. The sale represents part of the strategic review of the company, which will allow the company’s management to focus on the core operations. HSO’s Asian Pathology operations are operated under the Gribbles Pathology and Quest Laboratories brands. Moreover, in FY 17, the Asian Pathology operations had delivered EBITDA of A$18.2 million and A$9.6 million in 1H18, which represents approximately 4% of Group Operating EBITDA. The sale price reflects a FY17 EV/EBITDA multiple of 15.3x. Further, HSO expects to book a one-off gain on sale of approximately $165 million in relation to the transaction in the FY19 financial results. The company will be utilizing the net cash proceeds of the sale to pay down debt and fund the company’s expansion pipeline. Meanwhile, HSO stock has fallen 6.30% in three months as on July 27, 2018.

[pluginops_form template_id=’23834′ ]


Sponsored ad by Kalkine

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Facebook Comments
Join Our Forum

We help you to connect with investors and people connected with the stock market.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report


Please enter your comment!
Please enter your name here